Abstract
Drug delivery system (DDS), currently employed for cancer gene therapy was reviewed. There have been at least four systems hitherto developed to deliver the anticancer genes to tumor. They include 1) modified liposome system such as cationic liposorne, HVJ-liposme, transferrin conjugated liposome etc. 2) naked plasmid DNA conjugated with ligand or antibody which are known to interact with receptor or antigen on tumor cells. 3) viral vectors such as retroviral vector, adenoviral vector, lenti viral vector, adenoassociated viral vector etc. 4) replication competent oncolytic viruses such as E 1 B attenuated adenovirus or genetically modified herpes simplex virus. Although most of these delivery systems are found to be applicable for local administration of transgene, little success has been reported as to specific targeting to tumor by systemic administration. Therefore efforts are now focusing on the development of devise to target tumor in vivo.
